Search
News & Events
Seeking young people for energy drink studyAre you interested in sharing your thoughts about energy drinks in a group discussion? We are seeking young people to assist with our research.
News & Events
Kids with ADHD struggling at schoolA study by The Kids Research Institute Australia has found children with Attention Deficit Hyperactivity Disorder (ADHD) have significantly worse school outcomes.
News & Events
A New Avenue For Controlling Rheumatic Heart Disease?Rheumatic heart disease (RHD) is the most important cause of acquired cardiovascular disease in children and young adults and the most common cause of multivalv
News & Events
Rockingham to trial innovative pregnancy care programRockingham women are being urged to take part in a program trial aimed at guiding and supporting mums-to-be through a safe and healthy pregnancy.
News & Events
$20 million partnership a win for WA kidsIn the largest donation in Telethon history, BHP Billiton has committed $20 million over the next five years to The Kids Research Institute Australia
News & Events
Telethon WeekendThe Kids Research Institute Australia will have a stand at the beneficiary expo during this year's Telethon weekend running October 25 and 26.
News & Events
HBF Stadium Open DayHBF Stadium & HBF Arena Open Days - Sunday 20 & 27 July The Kids researchers will be presenting to the public as part of the two open days.
News & Events
Latitudinal gradient in childhood diabetesNew research from Perth's The Kids Research Institute Australia has shown the local relevance of a worldwide pattern of increased risk of childhood type 1 diabetes.
Research
Introducing the ORIGINS project: a community-based interventional birth cohortNon-communicable diseases (NCDs) pose the greatest threat to human health globally. The dramatic rise in early onset NCDs - such as childhood obesity, the allergy epidemic and an increasing burden of mental ill health in children and youth - reflect the profound early impact of modern environments on developing systems.
Research
RSV prophylaxis use in high-risk infants in Western Australia, 2002-2013: a record linkage cohort studyThe monoclonal antibody, palivizumab is licensed for use in high-risk infants to prevent severe illness caused by respiratory syncytial virus (RSV). The level of its use and compliance with current jurisdictional guidelines which were amended in 2010, is unknown.